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Effects of diacerhein on granuloma induced cartilage breakdown in
the mouse
By Adrian R. Moore, Kevin J. Greenslade, Chandan A. S. Alam and Derek A. Willoughby
Department of Experimental Pathology, William Harvey Research Institute, Charterhouse Square,
London EC1M 6BQ, U.K.
Summary
Objective: Diacerhein, an anti-osteoarthritic agent, was tested for its ability to suppress synthesis of proinflammatory
cytokines in a model of granuloma-induced cartilage breakdown.
Design: 50 TO mice received a subcutaneous implant of cotton-wrapped rat femoral head cartilage for a period of
2 weeks. Animals (N = 10/group) were dosed daily with either 6 mg/kg p.o. diclofenac or diacetylrhein at 5, 15 or
50 mg/kg p.o. in 0.1 ml 1% gum tragacanth which served as a control. Implanted cartilages were assayed for
glycosaminoglycan (GAG) and hydroxyproline content. The surrounding granulomas were assayed for interleukin-1a
(IL-1a), tumour necrosis factor-a (TNF-a) and IL-6. Statistical analysis was by Mann–Whitney U test.
Results: Diclofenac had no significant effect on GAG or hydroxyproline content of implanted cartilage or on
granuloma cytokine concentrations. Diacerhein protected implanted cartilages against hydroxyproline loss, implanted
control cartilages contained 220 mg hydroxyproline compared with diacerhein at 5, 15 and 50 mg/kg which produced
a 21, 16 and 59% decrease in hydroxyproline loss compared with non-implanted controls (P Q 0.05, 0.05 and 0.001)
respectively. Diacerhein also protected against GAG loss at 5 mg/kg and 50 mg/kg, control cartilages contained 134 mg
GAG compared with diacerhein at 5 mg/kg and 50 mg/kg which produced a 24 and 38% decrease in GAG loss
respectively (P Q 0.05 for both). Diacerhein significantly reduced granuloma interleukin-1a content at 5 mg/kg (control
level of 2.4 mg/ml reduced by 58%; P Q 0.05), reduced TNF-a at 5 mg/kg and 15 mg/kg (reduced by 61%: P Q 0.01 and
49%: P Q 0.05 respectively; control level of 469 pg/ml) and reduced IL-6 at 15 mg/kg and 50 mg/kg (control level of
537 pg/ml reduced by 60 and 51%, respectively; P Q 0.01 for both).
Conclusions: The mechanism of the chondroprotective effects of diacerhein is not understood but may be explained
by a reduction in the concentrations of proinflammatory cytokines.
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Introduction
Rhein (1,8-dihydroxy-3-carboxyanthraquinone) is
the active metabolite of diacerhein, a drug which
is used in the treatment of osteoarthritis, marketed
in France by NEGMA laboratories under the
name ART850. The compound is without effect on
prostaglandin biosynthesis but shows anti-
osteoarthritic properties and chondroprotective
effects, as shown previously in animal models [1].
In vitro, rhein has been shown to inhibit
superoxide release from stimulated human neu-
trophils [2]. Diacerhein reduces thioglycolate
stimulated accumulation of macrophages in mouse
peritoneal cavities and reduces their phagocytic
ability [3]. It also reduces the ability of stimulated
human neutrophils to release glycosaminoglycan
(GAG) from slices of bovine nasal cartilage [4].
Interestingly there is also a report that rhein
changes the fluidity of lymphocyte membranes [5].
Together, these studies suggest that rhein could
have multiple effects on acute inflammatory and
immune-based chronic inflammatory diseases. In-
terference with cytokine synthesis or activation of
cells would explain some of these multiple effects
and provide a rationale for the chondroprotective
effects of diacerhein in osteoarthritis where
cytokines are believed to play a key role in
cartilage destruction. We have tested diacerhein in
a model of granuloma-induced cartilage degra-
dation and measured granuloma interleukin-1
(IL-1a), tumour necrosis factor-a (TNF-a) and
interleukin-6 (IL-6) together with cartilage GAG
and hydroxyproline.
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Materials and Methods
chemicals and biochemicals
Standard reagents for buffers etc. were pur-
chased from Merck Ltd. and were of Analar grade.
Biochemical reagents were from Sigma Chemical
Company with the exception of 1,9-dimethyl-
methylene blue (Aldrich). Diacerhein, lot (YO
8501, was supplied by Madaus Aktigengesellschaft.
removal of rat femoral head cartilage
Male Wistar rats (150 2 10 g) were killed by
cervical dislocation. Femoral head cartilages were
removed using aseptic technique and stored in
sterile Hank’s balanced salt solution. A number of
cartilages were stored frozen at −20°C as non-im-
planted controls.
implantation
Cotton squares of 5.0 2 0.2 mg were cut from the
outer casing of dental rolls and autoclaved before
use. The squares were moistened with Hank’s
balanced salt solution and each cartilage was
placed, convex surface down, into the middle of a
cotton square. The corners were gathered over the
cartilage and tucked into the subchondral cavity.
Female TO mice (21.5 2 0.5 g, N = 10 per group)
were lightly anesthetized with halothane. Cotton-
wrapped cartilage was implanted subcutaneously
and wounds closed with 5 mm Michel clips. Mice
were killed by cervical dislocation 2 weeks
post-implantation and implants were excised. The
granulomas were then incised to remove the
cartilages which were digested for biochemical
analysis. The cotton granulomas were stored under
liquid nitrogen before cytokine assay. In some
cases the granulomas could not be dissected as
discrete entities. In these circumstances the
material was not used for cytokine analysis as
there would have been an unknown contribution
from surrounding tissues.
dosing
The drugs were administered daily by oral
gavage from the time of implantation. Drugs were
prepared immediately prior to use as suspensions
in 1% gum tragacanth and administered in a
volume of 0.1 ml. Doses corresponded to 6 mg/kg
for diclofenac and 5, 15 and 50 mg/kg for
diacerhein. Control animals received 0.1 ml of gum
tragacanth.
cartilage digestion
Cartilages were digested for 2 h at 56°C in 1 ml
0.05 m phosphate buffer (pH 7.0) supplemented
with N-acetyl-l-cysteine (2 mm) and papain (EC
3.4.22.2, 6 U/ml).
gag assay
GAG was assayed spectrophotometrically using
1,9 dimethylmethylene blue [6].
hydroxyproline assay
Hydroxyproline was assayed spectrophotometri-
cally by the method of Woessner [7].
murine cytokine assays
Cotton granulomas were homogenised in 1 ml
0.05 m Tris buffer (pH 7.6) supplemented with
2 mg/l pepstatin A, 2 mg/l leupeptin and 44 mg/l
phenylmethylsulfonyl fluoride. Aliquots were as-
sayed in duplicate using commercial enzyme-
linked immunosorbent assay (ELISA) kits
(Genzyme).
statistical analysis
Results were analysed using Mann–Whitney U
tests. A value of P Q 0.05 was considered statisti-
cally significant.
Results
Mean animal weights for each group showed a
similar increase over the 2 weeks implantation
period (data not shown). However, five of the
diclofenac-treated animals died before the end of
the experiment; cause of death was not established.
Diclofenac at 6 mg/kg has been used on a number
of occasions in this model without apparent
ill-effects.
Non-implanted control cartilages had a mean
GAG content of 275 mg (s.e.m. = 219 mg) and a
mean hydroxyproline content of 644 mg
(s.e.m. = 262 mg). Cartilages from all implanted
groups showed significant reductions in both GAG
and hydroxyproline contents. The GAG and
hydroxyproline content of implanted cartilages are
shown in Fig. 1. Implanted control cartilages had
a mean GAG content of 134 mg (s.e.m. = 214 mg)
and a mean hydroxyproline content of 221 mg
(s.e.m. = 219 mg). Treatment with diclofenac
showed no tendency to spare implanted cartilage
from GAG loss (128 2 20 mg, a 4% increase in GAG
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loss). However, cartilages from the diacerhein
groups showed a tendency to decrease GAG loss
compared with the implanted controls (168 2 7 mg,
a 24% decrease; 166 2 23 mg, a 23% decrease and
188 2 17 mg, a 38% decrease in GAG loss for 5, 15
and 50 mg/kg respectively) with statistically sig-
nificant differences in the 5 and 50 mg/kg groups
(P Q 0.05 for both).
Figure 1 also shows hydroxyproline contents of
implanted cartilages. Cartilages from the diclofe-
nac group showed a tendency to have reduced
hydroxyproline loss compared with the implanted
controls (278 2 13 mg, 26% decrease in hydroxypro-
line loss), however this was not statistically
significant. Cartilages from the diacerhein groups
at 5, 15 and 50 mg/kg all had hydroxyproline
contents greater than the implanted controls
(311 2 25 mg, 21%; 290 2 12 mg, 16% and
471 2 38 mg, 59% decrease in hydroxyproline loss
compared to implanted controls for 5, 15 and
50 mg/kg, respectively), with statistical differences
of P Q 0.05, P Q 0.05 and P Q 0.001 for 5, 15 and
50 mg/kg, respectively. The hydroxyproline loss for
the 50 mg/kg group was also significantly less than
that of the diclofenac group (P Q 0.01).
Granuloma cytokine concentrations are shown
in Fig. 2. Although granulomas from the diclofenac
treated group tended to show an increase in IL-1a
levels (33%) this was not statistically significant.
All granulomas from the diacerhein dosed groups
tended to have reduced levels of IL-1a (58, 31 and
37%, respectively) which in the case of the 5 mg/kg
Fig. 2. The effects of diclofenac and diacerhein on
granuloma interleukin-1a (mg/ml), tumour necrosis
factor-a (pg/ml) and interleukin-6 (pg/ml) content from
cotton wrapped cartilages that had been implanted
subcutaneously into mice for 2 weeks. Means 2 s.e.m.
*P Q 0.05, **P Q 0.01 comparison with vehicle control
(group numbers in parentheses).
Fig. 1. The effects of diclofenac and diacerhein on
cartilage hydroxyproline (plain bars) and glycosamino-
glycan (shaded bars) content of cotton wrapped
cartilages that had been implanted subcutaneously into
mice for 2 weeks. Means 2 s.e.m. *P Q 0.05, ***P Q 0.001
comparison with vehicle control (group numbers in
parentheses).
group was a statistically significant decrease in
comparison with the implanted control group
(P Q 0.05).
Diclofenac raised levels of TNF-a in granulomas
(5% increase) but not to a significant level.
Diacerhein decreased TNF-a concentrations in all
groups (61, 49 and 31% decreases with 5, 15 and
50 mg/kg, respectively) with statistically signifi-
cant differences in the 5 and 15 mg/kg groups
(P Q 0.01 and P Q 0.05, respectively).
Granulomas from the diclofenac treated group
had raised IL-6 levels but this was not a
statistically significant increase (11% increase).
Dosing with diacerhein decreased IL-6 concen-
trations in all groups (32, 60 and 51% decreases for
5, 15 and 50 mg/kg, respectively) with statistically
significant differences in the 15 and 50 mg/kg
groups (P Q 0.01 for both).
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Discussion
The cotton-cartilage implant model has a
number of advantages over many of the conven-
tional models of arthritis. First, the cartilage can
be recovered easily at the end of the implantation
period for biochemical analysis, a 2-week period of
implantation being suitable for assessing proteo-
glycan and collagen degradation [8].
Second, the surrounding granuloma is a discrete
entity that can be assayed for inflammatory
mediators including cytokines [9]. Finally, and
most importantly, the results of screening a range
of anti-inflammatory and slow acting anti-rheu-
matics have suggested that the model is able to
discriminate between these classes of drugs to a
greater extent than other animal models of
arthritis. Nonsteroidal anti-inflammatory drugs
(NSAIDs) including indomethacin, and in particu-
lar, diclofenac have a tendency to accelerate
matrix degradation. Steroids, such as dexametha-
sone, are protective and various immunomodula-
tors or proposed disease modifiers are without
effect or protective [8, 10].
This is not the first time diclofenac and
diacerhein have been examined in the murine
model of granuloma-induced cartilage breakdown.
In a previous study diacerhein appeared to protect
against proteoglycan breakdown (reduction in
GAG losses compared with the non-implanted
control were diclofenac 6 mg/kg 6%; diacerhein
50 mg/kg 12%) and collagen breakdown (diclofe-
nac 6 mg/kg 11% reduction in hydroxyproline loss;
diacerhein 50 mg/kg showed no hydroxyproline
loss compared with the non-implanted control).
These results have now been confirmed and
extended and it is important to note the the doses
for diacerhein used in these studies result in steady
state plasma concentrations that do not exceed
those obtained in the clinic (Dr Ficheux, personal
communication). This is not an anti-inflammatory
effect per se because in these previous studies we
were unable to show significant changes in dry
weights of the granuloma (control 14.1 2 1.3 mg;
diclofenac 6 mg/kg 13.6 2 2.1 mg; diacerhein
50 mg/kg 13.7 2 1.5 mg).
Cartilage degradation is thought to occur in two
stages, first the loss of proteoglycan and then the
loss of collagen. Whilst loss of proteoglycan is
thought to be readily reversible, degradation of
collagen is thought to be more difficult, if not
impossible, to reverse. Considerable efforts are
being made to produce matrix metalloprotease
inhibitors as therapeutic agents in chondrode-
structive pathologies [11]. An alternative approach
is to target those mediators that are responsible for
proteolytic enzyme production. Of these, the
catabolic cytokines IL-1 and TNF are considered
to be of particular importance. These cytokines
are detrimental to cartilage through stimulating
synovial fibroblasts and cartilage chondrocytes to
secrete matrix metalloproteases and hindering
repair through suppressing chondrocyte synthesis
of proteoglycan and collagen II [12]. In addition,
these cytokines contribute to the disease state by
enhancing T-lymphocyte function [13], causing
expression of adhesion molecules on endothelial
cells and stimulating leukocyte accumulation [14]
and proliferation of fibroblasts [15]. The marked
potentiation of each cytokine on the actions of the
other suggest that reducing the concentration or
antagonising the actions of either could have a
marked therapeutic effect. Initial trials with
anti-cytokine antibodies were encouraging but
even with ‘humanized’ antibodies there is danger
of an antiidiotypic response [16].
There may be many mechanisms through which
diacerhein exerts its activity, but in this study we
have concentrated on possible effects on synthesis
of IL-1a, TNF-a and IL-6. These cytokines were
measured in the cotton granulomas at the end of
the experiment. Interestingly, the reference com-
pound, diclofenac, appeared to increase cytokine
production. If this property is shared with other
NSAIDs this could help explain accelerated matrix
loss seen with many NSAIDs in this model [8, 10].
In contrast diacerhein, at all doses tested, reduced
granuloma cytokine concentrations. However, the
greatest chondroprotective effect was seen at
50 mg/kg whereas optimum cytokine suppression
occurred at differing doses for differing cytokines.
To what extent this reflects differing actions on
intracellular or extracellular cytokines is not
known. However the data suggest that the
chondroprotective actions of diacerhein are in part
through reduction in granuloma IL-1a, TNF-a and
IL-6 concentrations, but that unidentified ad-
ditional activities may play a role.
This study has focused on just three cytokines,
but it is not unreasonable to suppose that
diacerhein may have an affect on a range of
cytokines, both proinflammatory and anti-inflam-
matory. Reducing the concentrations of IL-1 and
TNF is clearly linked to chondroprotective effects.
It is less certain that reductions in IL-6 would
equally be chondroprotective since this cytokine in
addition to activating B and T-cells has been
linked to induction of protease inhibitors [17]. A
full study of the effects of diacerhein on the
balance of proinflammatory and anti-inflammatory
cytokines is required. However, the data from this
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study would indicate that the net effect results in
chondroprotection.
In conclusion, diacerhein compared very favour-
ably with diclofenac in terms of its tolerance and
chondroprotective activities in the murine model
of granuloma-mediated cartilage breakdown. Some
of these actions may be due to a reduction in
granuloma concentrations of IL-1a, TNF-a and
IL-6.
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